By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Helsinn Healthcare SA 

6912 Pazzallo-Lugano

Via Pian Scairolo    9  Switzerland
Phone: 41-91-985-21-21 Fax: +41-91-993-21-22


Helsinn is a privately owned cancer care pharmaceutical group with an extensive portfolio of marketed products and a broad development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality, through a unique integrated licensing business model working with long standing partners in pharmaceuticals, medical devices and nutritional supplement products. Helsinn is headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland and the US, a representative office in China, as well as a product presence in about 90 countries globally.




Please click here for Helsinn job opportunities.


All Products


Key Statistics

Ownership: Private

Web Site: Helsinn


Company News
Helsinn Group Announces Upcoming Presentation Of Phase III Data In NEPA (Netupitant/Palonestron) At MASCC/ISOO Congress In Washington DC 6/20/2017 9:32:57 AM
Helsinn And MEI Pharma (MEIP) Announce First Patient Dosed In Phase II Dose-Optimization Study Of Pracinostat And Azacitidine In Myelodysplastic Syndrome 6/14/2017 6:50:07 AM
Helsinn Passes On Zealand Pharma  (ZEAL.CO)'s Chemotherapy-Induced Diarrhea Med 6/12/2017 6:46:02 AM
Helsinn And MEI Pharma (MEIP) Report Correlation Between Mutations In DNA Methylation Pathway And Clinical Response In Phase II Study Of Pracinostat And Azacitidine In Acute Myeloid Leukemia 6/5/2017 7:45:18 AM
Helsinn Advanced Synthesis Wins Across All Categories At 2017 CMO Leadership Awards 3/23/2017 9:11:45 AM
Helsinn Collaborates With Lyfebulb To Support Patient-Driven Innovations For People With Cancer 3/21/2017 9:22:12 AM
Helsinn Provides Grant For ESMO’s Preceptorship Course On Supportive And Palliative Care 2/15/2017 7:02:40 AM
Mundipharma AG And Helsinn Expand Exclusive Licensing And Distribution Agreements For Leading Anti-emetic Products In Middle East, Africa, Latin America And Indonesia 2/14/2017 8:39:45 AM
Helsinn And MEI Pharma (MEIP) Report Prolongation Of Survival Results From Phase 2 Clinical Study Of Pracinostat And Azacitidine In Acute Myeloid Leukemia 12/5/2016 6:43:05 AM
Helsinn And MEI Pharma (MEIP) Announce Long-Term Survival And Response Data From Phase II Clinical Study Of Pracinostat In Acute Myeloid Leukemia Accepted For Oral Presentation At Upcoming American Society of Hematology Annual Meeting 11/3/2016 7:52:17 AM